Viridian Therapeutics, Inc.\DE
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended December 31, 2025, the following directors or officers of the Company adopted or terminated a “Rule 10b5-1 trading arrangement,” as defined in Item 408 or Regulation S-K:
| Name and Title | Plan Action | Plan Adoption Date | Expiration Date | Number of Shares to be Sold under Plan |
|---|---|---|---|---|
| Thomas Beetham, Chief Operating Officer | Adoption | 12/12/2025 | 12/18/2026 | 30,000 |
| Stephen Mahoney, President & Chief Executive Officer | Adoption | 12/17/2025 | 12/31/2026 | 250,000 |
| Seth Harmon, Chief Financial Officer | Adoption | 12/22/2025 | 12/31/2026 | 20,907 |
During the three months ended December 31, 2025, none of the Company’s officers or directors adopted orterminated any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 or Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.